Stockreport

Esperion Therapeutics Touts 38% Revenue Growth, Corstasis Deal and 2026 Cash-Gen Path at Conference [Yahoo! Finance]

Esperion Therapeutics, Inc.  (ESPR) 
Last esperion therapeutics, inc. earnings: 2/27 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.esperion.com
PDF The company is acquiring Corstasis and its nasal heart-failure drug ENBUMYST , a deal expected to close in the first week of April for $75 million upfront plus ~ $180 m [Read more]